GlassScriptPhysician profile
Melanie Teasley
NPI 1528157682
$1,949.82
in general payments reported to CMS, 2019-2025
15 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $177 · 2021: $455 · 2022: $274 · 2024: $96.69 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.03 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.89 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $242.57 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $228.74 | 2019-2022 | |
| Lundbeck LLC | $225.54 | 2019-2022 | |
| Allergan, INC. | $195.21 | 2019-2020 | |
| Alkermes, INC. | $156.17 | 2020-2025 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $139.69 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $56.99 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $46.34 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $38.61 | 2019 | |
| Ironshore Pharmaceuticals INC. | $27.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.72 | 2022 | |
| Adlon Therapeutics L.P. | $12.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Teasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.